About the Company
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
562
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VIR News
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $64.8, a high estimate of $110.00, and a low estimate of $9.00. This current average has increased by ...
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
S hares of Vir Biotechnology, Inc. (VIR) have gained 6.2% over the past four weeks to close the last trading session at $10.30, but there could still be a solid upside left in the stock if short ...
Q4 2023 Vir Biotechnology Inc Earnings Call
Sasha Damouni Ellis; Executive Vice President and Chief Corporate Affairs Officer; Vir Biotechnology Inc Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc Phil Pang ...
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of ...
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vir Biotechnology (VIR – Research Report) ...
Vir Biotechnology files patent for antibodies for detecting, treating, and preventing metapneumovirus infection
Discover a groundbreaking patent by Vir Biotechnology targeting metapneumovirus (MPV) infection. Learn about novel antibodies with high specificity and efficacy in neutralizing MPV across subgroups.
VIR Oct 2024 22.500 call
SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and ...
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time ...
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Stay well-informed and make prudent decisions using our Ratings Table. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious ...
Loading the latest forecasts...